AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ARQT · NASDAQ · Biotechnology

Arcutis Biotherapeutics (ARQT)

Develops ZORYVE topical treatments for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.

$26.29

vs last close−1.49 (−5.36%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	38	14	50	31	45	71	66	82	99	130	105	130
Cost of revenue	1	2	3	3	6	7	9	7	9	12	10	11
Gross profit	37	11	46	27	39	64	57	74	91	118	96	119
	74	72	78	77	78	72	82	89	82	99	105	102
Research & development	26	24	23	19	20	14	18	19	20	20	31	20
	48	49	55	58	59	58	64	69	62	79	74	82
General & administrative	0	0	0	0	0	0	0	0	0	0	0	82
Operating income	−37	−61	−32	−50	−39	−8	−25	−15	9	18	−9	16
	−5	−5	−3	−2	−2	−3	0	−1	−1	−1	−2	−1
Interest income	0	0	0	0	0	0	0	0	0	0	2	2
Interest expense	8	8	7	7	7	6	3	3	3	3	4	3
Other non-operating income	−3	−3	−4	−5	−4	−3	−3	−2	−2	−2	−2	0
Income before tax	−42	−66	−35	−52	−42	−10	−25	−16	7	18	−11	15
Income tax expense	3	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−45	−66	−35	−52	−42	−11	−25	−16	7	17	−11	15
Net income	−45	−66	−35	−52	−42	−11	−25	−16	7	17	−11	15
EPS, basic	−$0.73	−$0.72	−$0.32	−$0.42	−$0.33	−$0.09	−$0.20	−$0.13	$0.06	$0.14	−$0.09	$0.11
EPS, diluted	−$0.73	−$0.72	−$0.32	−$0.42	−$0.33	−$0.09	−$0.20	−$0.13	$0.06	$0.13	−$0.09	$0.11
Weighted average shares, basic	62	93	111	123	124	121	126	127	128	128	129	131
Weighted average shares, diluted	62	93	111	123	124	121	126	127	133	136	129	136
EBITDA	−34	−58	−27	−44	−33	−4	−19	−12	11	22	−6	17
Depreciation & amortization	0	0	0	0	1	0	3	1	1	1	1	1
EBIT	−34	−58	−28	−45	−35	−5	−22	−13	11	21	−7	17